Market Cap
$17.0B
ZBH
ZIMMER BIOMET HOLDINGS, INC.
$87.94 ▼ -0.14%
Prev close $88.06Market cap$17.0B
ConsensusSell
12-mo target$107.57 (+22.4%)
▼ Bearish
Analyst conviction 3/10
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)42 New Institutional Positions8 Institutional ExitsCongressional Activity (2) Healthcare & Medical Devices
Snapshot
The big-picture read on ZBH right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Hold (33%)
Inst. Holders
50 funds
Inst. Value
$13.8B
Inst. Activity
42 buys / 8 sells
Insider Activity
$0.00 buy / $1.5M sell
Insider Net $
-$1.5M
SEC Reports
9
Congressional
2 trades
Price chart 30d -11.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 short_volume
Sep 16, 2026 SEC Short Volume: ZBH — 59.9% short (0.3M / 0.5M)
Short: 328,494 | Exempt: 1,504 | TRF Vol: 548,773 | Short Ratio: 59.9% | Off-exchange volume (dark p
Two insider sells totaling $824K at Zimmer Biomet over the past 30 days. The dollar value is modest relative to the comp
CLUSTER — Impact 3/10
Sep 11, 2026 Insider
Sep 4, 2026 SEC Thornal Kevin R sold 5,691 shares
Grp Pres-Global Business @ $92.95 ($529.0K)
Judge Lindsay denied Zimmer Biomet's motion for judgment on the pleadings in a single-plaintiff metallosis hip implant c
COURT-RULING — Impact 2/10
Sep 4, 2026 Insider
Phipps Chad F sold 3,000 shares
See remarks below. @ $98.35 ($295.1K)
Sep 2, 2026 Event
Aug 18, 2026 SEC Morrison v. Zimmer Biomet Holdings Inc et al
Court ruling (txnd) — Docket: 3:24-cv-01003
A New Jersey federal district court issued a procedural order in a product-liability case against Zimmer Biomet, grantin
COURT-RULING — Impact 2/10
Aug 3, 2026 Insider
Desai Chintan was granted 10,168 shares
President, APAC
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
33% rate it Buy or better · 33 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 10, 2026 | Canaccord Genuity | MAINTAIN | Hold | 47% |
| Aug 7, 2026 | Truist Securities | MAINTAIN | Hold | 55% |
| Aug 6, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Aug 6, 2026 | Bernstein | MAINTAIN | Market Perform | 51% |
| Aug 6, 2026 | Stifel | MAINTAIN | Buy | 54% |
| Jul 9, 2026 | BMO Capital | INITIATE | Market Perform | 53% |
| Jul 6, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| May 28, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
| Apr 29, 2026 | JP Morgan | MAINTAIN | Neutral | 55% |
| Apr 29, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 8 | 22 | 0 | 0 | 33% | |
| Aug 1, 2026 | 3 | 8 | 22 | 0 | 0 | 33% | |
| Jul 1, 2026 | 4 | 8 | 20 | 2 | 0 | 35% | |
| Jun 1, 2026 | 4 | 8 | 20 | 2 | 0 | 35% | |
| May 1, 2026 | 3 | 8 | 21 | 3 | 0 | 31% | |
| Apr 1, 2026 | 3 | 8 | 20 | 3 | 0 | 32% | |
| Mar 1, 2026 | 4 | 8 | 20 | 3 | 0 | 34% | |
| Feb 1, 2026 | 4 | 8 | 19 | 3 | 0 | 35% |
Price targets
Where 21 covering analysts think ZBH trades over the next 12 months.
$107.57 +22.4% upside Strong Buy
Current$87.86 Low$93.00 Median$106.00 High$130.00 21 analysts
$93.00$130.00
Analyst rating Buy· 2.4/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 2 bullish, 0 bearish, 0 mixed, 7 neutral · avg impact 3.8/10.
NEUTRALCLUSTER3/10
Two insider sells totaling $824K at Zimmer Biomet over the past 30 days. The dollar value is modest
Sep 16, 2026
NEUTRALCOURT-RULING2/10
Judge Lindsay denied Zimmer Biomet's motion for judgment on the pleadings in a single-plaintiff meta
Sep 4, 2026
NEUTRALCOURT-RULING2/10
A New Jersey federal district court issued a procedural order in a product-liability case against Zi
Aug 18, 2026
BULLISH8-K6/10
Zimmer Biomet reported Q2 2026 adjusted EPS of $2.07, a 3.0% beat vs. consensus of $2.01, on revenue
Aug 5, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
short_volume
Short Volume: ZBH — 59.9% short (0.3M / 0.5M)
Short: 328,494 | Exempt: 1,504 | TRF Vol: 548,773 | Short Ratio: 59.9% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_volume
Short Volume: ZBH — 72.0% short (1.3M / 1.8M)
Short: 1,289,042 | Exempt: 132 | TRF Vol: 1,791,258 | Short Ratio: 72.0% | Off-exchange volume (dark pool + OTC)
Sep 14, 2026
short_volume
Short Volume: ZBH — 55.9% short (0.5M / 0.8M)
Short: 462,211 | Exempt: 10,308 | TRF Vol: 826,569 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
Sep 9, 2026
short_volume
Short Volume: ZBH — 71.8% short (0.5M / 0.7M)
Short: 493,595 | Exempt: 861 | TRF Vol: 687,215 | Short Ratio: 71.8% | Off-exchange volume (dark pool + OTC)
Sep 8, 2026
short_volume
Short Volume: ZBH — 61.1% short (0.8M / 1.3M)
Short: 795,180 | Exempt: 336 | TRF Vol: 1,302,479 | Short Ratio: 61.1% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $1.88 | $1.86–$1.91 | -0.9% | +0.0% | 12↑ 7↓ | $2.0B | 24 |
| Next Q | $2.49 | $2.43–$2.54 | 3.0% | +0.0% | 4↑ 15↓ | $2.3B | 24 |
| Current FY | $8.53 | $8.49–$8.57 | 4.1% | +0.0% | 22↑ 1↓ | $8.6B | 27 |
| Next FY | $9.07 | $8.77–$9.58 | 6.3% | -0.0% | 19↑ 5↓ | $8.9B | 27 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.882 | — |
| 7d ago | $1.882 | — |
| 30d ago | $1.882 | — |
| 60d ago | $1.878 | +0.004 |
| 90d ago | $1.876 | +0.006 |
Institutional ownership
Which big funds own ZBH (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $13.8B total value (160,351,920 shares) as of 2026-Q2. Top holders: DODGE, BlackRock,, HARRIS. Net buying activity: 42 institutions added/increased vs 8 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| DODGE & COX | 24,124,735 | $2.1B | 15.0% | — |
| BlackRock, Inc. | 15,614,847 | $1.3B | 9.7% | — |
| HARRIS ASSOCIATES L P | 12,738,025 | $1.1B | 7.9% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 12,634,937 | $1.1B | 7.9% | — |
| Capital International Investors | 12,183,614 | $1.0B | 7.6% | ADD +33.6% |
| STATE STREET CORP | 8,877,171 | $766.3M | 5.5% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 8,441,747 | $726.7M | 5.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 5,349,223 | $458.7M | 3.3% | — |
| Invesco Ltd. | 3,979,860 | $342.6M | 2.5% | — |
| PRIMECAP MANAGEMENT CO/CA/ | 3,816,680 | $328.6M | 2.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Capital International Investors | ADD | 9,119,222 | 12,183,614 | +33.6% | $1.0B |
| CITADEL ADVISORS LLC | DOUBLED | 1,378,665 | 3,477,472 | +152.2% | $299.4M |
| UBS Group AG | DOUBLED | 1,373,365 | 2,758,615 | +100.9% | $237.5M |
| AMERICAN CENTURY COMPANIES INC | TRIM | 3,963,206 | 2,744,463 | -30.8% | $236.3M |
| MORGAN STANLEY | ADD | 2,029,815 | 2,591,503 | +27.7% | $223.1M |
| BANK OF AMERICA CORP /DE/ | ADD | 1,549,790 | 2,177,724 | +40.5% | $187.5M |
| NORGES BANK | NEW | — | 1,587,431 | — | $136.7M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | 1,104,218 | 1,562,139 | +41.5% | $134.5M |
| Holocene Advisors, LP | ADD | 593,705 | 1,177,461 | +98.3% | $101.4M |
| TORONTO DOMINION BANK | DOUBLED | 58,097 | 947,731 | +1531.3% | $81.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
17 insiders, 50 transactions. Net -$1.5M — $0.00 bought, $1.5M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Thornal Kevin R | Grp Pres-Global Business | SELL | 5,691 | $92.95 | $529.0K |
| Sep 4, 2026 | Phipps Chad F | See remarks below. | SELL | 3,000 | $98.35 | $295.1K |
| Aug 3, 2026 | Desai Chintan | President, APAC | AWARD | 10,168 | — | — |
| Aug 1, 2026 | Thornal Kevin R | Grp Pres-Global Business | EXERCISE | 9,957 | — | — |
| Aug 1, 2026 | Thornal Kevin R | Grp Pres-Global Business | TAX W/H | 4,266 | $92.68 | $395.4K |
| Jun 30, 2026 | HAGEMANN ROBERT | Director | AWARD | 317.369 | — | — |
| Jun 30, 2026 | Hilado Maria Teresa | Director | AWARD | 389.498 | — | — |
| Jun 30, 2026 | Kurdikar Devdatt | Director | AWARD | 180.323 | — | — |
| Jun 30, 2026 | Kolli Sreelakshmi | Director | AWARD | 180.323 | — | — |
| Jun 30, 2026 | Farrell Michael J. | Director | AWARD | 432.776 | — | — |
Congressional trades
ZBH trades disclosed by members of Congress, with disclosure delay.
1 members · 0 buys / 2 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Jul 23, 2026 | Ro Khanna | D | HOUSE | SELL | $1,001 - $15,000 | Zimmer Biomet Holdings Inc | Aug 12, 2026(21d) |
| Jul 6, 2026 | Ro Khanna | D | HOUSE | SELL | $1,001 - $15,000 | Zimmer Biomet Holdings Inc | Aug 12, 2026(38d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ZBH.
Shares short
8,576,677
Settlement Sep 15, 2026
Change vs prior
-2.4%
Semi-monthly cycle
Days to cover
4.4
At avg daily volume
Of shares outstanding
≈4.5%
Estimate — not % of float
All ZBH filing & press-release reports (9)
- CLUSTER reportSep 16, 2026
- COURT-RULING reportSep 4, 2026
- COURT-RULING reportAug 18, 2026
- 8-K reportAug 5, 2026
- 8-K reportMay 12, 2026
- COURT-RULING reportMay 1, 2026
- 8-K reportApr 28, 2026
- 8-K reportApr 28, 2026
- DEFA14A reportApr 1, 2026